Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia

Synapse

Volumn 65, Issue 2, 2011, Pages 119-124

  Chen, Sheng ^a   Seeman, Philip ^b   Liu, Fang ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Clozapine; Haloperidol; Metoclopramide; Olanzapine; Schizophrenia; Substantia nigra; Tardive dyskinesia

Indexed keywords

CLOZAPINE; HALOPERIDOL; LIGAND; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; CEREBROSPINAL FLUID; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG BINDING; DRUG BLOOD LEVEL; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; INCIDENCE; MEMBRANE DAMAGE; MULTIPLE SCLEROSIS; NERVE CELL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HUNTINGTON DISEASE; METOCLOPRAMIDE; MOVEMENT DISORDERS; MULTIPLE SCLEROSIS; PROTEIN BINDING; RATS; SUBSTANTIA NIGRA; TRITIUM;

EID: 78650023373     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20825     Document Type: Article

References (38)

1. Bateman DN, Kahn C, Davies DS. 1979. Concentration effect studies with oral metoclopramide. Br J Clin Pharmacol 8: 179-182.
2. Bateman DN, Kahn C, Legg NJ, Reid DM. 1978. Metoclopramide in Parkinson's disease. Clin Pharmacol Ther 24: 459-464.
3. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. 1999. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 174: 23-30.
4. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. 1994. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151: 123-125.
5. Christensen E, Moller JE, Faurbye A. 1970. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiat Scand 46: 14-23.
6. Cochlin DL. 1974. Dystonic reactions due to metoclopramide and phenothiazines resembling tetanus. Br J Clin Pract 28: 201-202.
7. Coryell W, Kelly M, Perry PJ, Miller DD. 1990. Haloperidol plasma levels and acute clinical change in schizophrenia. J Clin Psychopharmacol 10: 397-402.
8. Csernansky JG, Mahmoud R, Brenner R. 2002. Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22.
9. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M. 2000. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 15: 506-514.
10. Ezrin-Waters C, Seeman MV, Seeman P. 1981. Tardive dyskinesia in schizophrenic outpatients: Prevalence and significant variables. J Clin Psychiat 42: 16-22.
11. Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G. 1988. An open label trial of raclopride in acute schizophrenia. Confirmation of D2 dopamine receptor occupancy by PET. Psychopharmacology 94: 1-7.
12. Ganzini L, Casey DE, Hoffman WF, McCall AL. 1993. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469-1475.
13. Grimes JD. 1981. Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy. New Engl J Med 305: 1417.
14. Jeste DV, Okamoto A, Napolitano J, Kane JM, Marrinez RA. 2000. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 157: 1150-1155.
15. Kane JM. 2004. Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J Clin Psychiatry 65: 16-20.
16. Kane JM, Smith JM. 1982. Tardive dyskinesia: Prevalence and risk factors; 1959 to 1979. Arch Gen Psychiatry 39: 473-481.
17. Kataria M, Traub M, Marsden CD. 1978. Extrapyramidal side effects of metoclopramide. Lancet ii: 1254.
18. Kirch DG, Bigelow LB, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ. 1988. Serum haloperidol concentration and clinical response in schizophrenia. Schizophrenia Bull 14: 283-289.
19. Lavy S, Melamed E, Penchas S. 1978. Tardive dyskinesia associated with metoclopramide. Brit Med J 14: 77-78.
20. Lemmens P, Brecher M, Van Baelen B. 1999. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms. Acta Psychiatrica Scand 99: 160-170.
21. Lieberman JA, Johns C, Pollack S, Masiar S, Bookstein P, Cooper T, Iadorola M, Kane J. 1991. Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia. In: Tamminga CA, Schulz SC, editors. Advances in Neuropsychiatry and Psychopharmacology, Vol. 1. Schizophrenia Research. New York: Raven Press. p 341-349.
22. Lydén A, Larsson B, Lindquist NG. 1982. Studies on the melanin affinity of haloperidol. Arch Int Pharmacodyn Ther 259: 230-243.
23. Nielsen EB, Lyon 1978. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drugs (flupenthixol) in rats. Psychopharmacology 59: 85-89.
24. Pakkenberg H, Fog R, Nilakantan B. 1973. The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical findings. Psychopharmacologia (Berl) 29: 329-336.
25. Perry PJ, Lund BC, Sanger T, Beasley C. 2001. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21: 14-20.
26. Rivera-Calimlim L, Gift T, Nasrallah HA, Wyatt RJ, Lasagna L. 1978. Correlation between plasma concentrations of chlorpromazine and clinical response. Commun Psychopharmacol 2: 215-222.
27. Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. 1998. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 46: 453-459.
28. Seeman MV. 1981. Tardive dyskinesia: Two year recovery. Compr Psychiatry 22: 189-192.
29. Seeman P. 1966. Erythrocyte membrane stabilization by local anesthetics and tranquilizers. Biochem Pharmacol 15: 1753-1766.
30. Seeman P. 1988. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 8(4 Suppl): 3S-9S.
31. Seeman P. 1992. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology 7: 261-284.
32. Seeman P, Bialy H. 1963. The surface activity of tranquilizers. Biochem Pharmacol 12: 1181-1191.
33. Sigwald J, Bouttier C, Raymondeaud C, Piot C. 1959. Quatre cas de dyskinésie facio-bucco-linguo-masticatrice a evolution prolonguée secondaire a un traitement par les neuroléptiques. Rev Neurol 100: 751-755.
34. Spina E, de Leon J. 2007. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin Pharmacol Toxicol 100: 4-22.
35. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D. 1980. Metoclopramide: Antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology 71: 219-225.
36. Tollefson GD, Beasley CMJr, Tamura RN, Tran PV, Potvin JH. 1997. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248-1254.
37. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou JC, Crowner M. 1992. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49: 354-361.
38. Webb D, Buss DC, Fifield R, Bateman DN, Routledge PA. 1986. The plasma protein binding of metoclopramide in health and renal disease. J Clin Pharmacol 21: 334-336.